CASE STUDY

Explaining the unexpected COVID-19 trends and potential impact across Africa. [version 2; peer review: 1 approved with reservations]

Daniel Oduro-Mensah¹,², Ebenezer Oduro-Mensah³, Peter Quashie²,⁴, Gordon Awandare¹,², Laud Okine¹,²

¹Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana
²West African Center for Cell Biology of Infectious Pathogens, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana
³Ga-East Municipal Hospital, Ghana Health Service, Accra, WY1895, Ghana
⁴Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra, LG 581, Ghana

First published: 22 Nov 2021, 10:1177
https://doi.org/10.12688/f1000research.74363.1
Latest published: 21 Nov 2022, 10:1177
https://doi.org/10.12688/f1000research.74363.2

Abstract
Official COVID-19 case counts and mortality rates across Africa are lower than had been anticipated. Research reports, however, indicate far higher exposure rates than the official counts in some countries. Particularly in Western and Central Africa, where mortality rates are disproportionately lower than the rest of the continent, this occurrence may be due to immune response adaptations resulting from (1) frequent exposure to certain pro-inflammatory pathogens, and (2) a prevalence of low-grade inflammation coupled with peculiar modifications to the immune response based on one’s immunobiography. We suggest that the two factors lead to a situation where post infection, there is a rapid ramp-up of innate immune responses, enough to induce effective defense and protection against plethora pathogens. Alongside current efforts at procuring and distributing vaccines, we draw attention to the need for work towards appreciating the impact of the apparently widespread, asymptomatic SARS-CoV-2 infections on Africa's populations vis a vis systemic inflammation status and long-term consequences for public health.

Keywords
COVID-19, Immunobiography, Inflamm-aging, Inflammation, Long COVID

This article is included in the Emerging Diseases and Outbreaks gateway.
List of abbreviations
COVID: coronavirus disease
LGI: low-grade inflammation
PASC: post-acute sequelae of COVID-19
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

Introduction
Despite predictions of being among the worst affected globally, the trajectory of COVID-19 in Africa has been radically different, with far lower morbidity and mortality figures than recorded in the United Kingdom, India, Brazil, the Americas, and across Europe. By March 2022, Africa contributed approximately 2% of global COVID-19 case counts. From December 2020, emerging SARS-CoV-2 variants have fuelled multiple waves of COVID-19 across the globe. Considering Africa’s relatively ill-resourced healthcare settings, mainly across sub-Saharan Africa, it was expected that COVID-19 patients who required hospital admission would be disproportionately more likely to die. However, Africa’s 17% share of the global population had contributed only up to 3% of global COVID-19 mortality by August 2022. Interestingly among Africa’s five regions, countries in Western and Central Africa appear to be least affected by the COVID-19 pandemic (Figure 1). As of September 2022, these two regions which make up 4% of Africa’s 1.4 billion population contributed only 13% of Africa’s COVID-19 morbidity and 8% of mortality figures.

Attempts at explaining Africa’s trends include suggestions that not enough testing has been done in the region, that Africa has a relatively young population, an impact of the systematic use of antimalarials in parts of Africa, and that the third-world conditions across most of the region may mean that people have previously been exposed to viruses molecularly similar to SARS-CoV-2. Others have suggested that exposure to similarly inflammatory conditions/

pathogens may have led to a situation where individuals have adapted to the effects of inflammation and so are less sensitive to the SARS-CoV-2-induced inflammatory events which are the main drivers of COVID-19 pathogenesis.32–35 Here, (1) we discuss evidence in support of the modification of the immune response due to frequent exposure to inflammatory pathogens, citing malaria, and (2) present a second reason to explain why most parts of Africa have been relatively spared the worst of COVID-19.

**Frequent exposure to malaria**

Approximately 85% of global malaria incidence is in Africa.26 Of Africa’s five regions, Western and Central Africa are reported to have the highest malaria incidence, contributing up to 71% of Africa’s total burden. In 2017, an inverse relationship between the pro-inflammatory response and exposure to malaria was reported.27 Contrastingly, naïve individuals exhibited a more pro-inflammatory response with higher circulating levels of pro-inflammatory immune mediators,28,29 which are essential in the clinical presentation of malaria. Individuals residing in malaria endemic zones often harbor *Plasmodium* spp. infections but are clinically immune.30,31 It has been suggested that repeated episodes of febrile malaria alter the immune response, resulting in a blunted inflammatory response which shows low levels of pro-inflammatory cytokines and appears to be dominated by anti-inflammatory cytokines.32 This likely plays a significant role in the apparent immunologic tolerance manifesting as clinical immunity to malaria.30,31,33 In addition, there appears to be the upregulation of certain components of the innate immune response, including phagocytes and interferon-gamma, in frequently exposed individuals.32,34,35 We suggest that this altered immune response, characterized by low pro-inflammatory mediator levels, high anti-inflammatory mediator levels and up-regulated innate immune components, offers some protection against SARS-CoV-2-induced inflammation.

In individuals with the altered response due to frequent malaria exposure, SARS-CoV-2 infection may be met by a heightened innate response which overwhelms the reported blocking of some innate immune response pathways by the virus.36–40 Our submission, therefore, is that although this heightened innate response is limiting to the virus, it does not elicit enough of a pro-inflammatory adaptive response which could lead to the classical COVID-19-associated hyperinflammation. Consequently, the result of SARS-CoV-2-induced inflammation is not the cytokine ‘storm’ that occurs in severe COVID-19, but a milder cytokine ‘drizzle’ that minimizes the deleterious effects of the inflammatory response. This is contrary to suggestions, including that by Kusi et al.,23 that the innate response may be negatively associated with the observed immunopathology of COVID-19. We maintain that viral load would effectively be suppressed by the innate response, consistent with suggestions by Stirz and Hale,26 with a slow ramp-up in inflammatory cytokine production due to the blunted pro-inflammatory adaptive response. Therefore, patients would only experience mild COVID-19 symptoms, or even have asymptomatic infections. A study on patients in China with asymptomatic COVID-19 revealed that they had relatively lower levels of serum alanine aminotransferase (ALT) and C-reactive protein.31 Previously, it has been shown that ALT may correlate negatively with T cell and natural killer cell activity.26 This then supports the suggestion that in individuals with asymptomatic infection, there may be a sharper cell-mediated innate response which significantly moderates the progression to a pro-inflammatory, adaptive immune response.

It is striking how patterns of malaria endemicity appear to contrast COVID-19 mortality patterns in several places across Africa. Countries with the least malaria are the most affected by COVID-related mortality (Figure 1). Only one (Nigeria) of the top ten malaria endemic countries in Africa was in the top ten of country reports on Africa’s COVID-19 mortality rates as of September 2021. This is likely to be because Nigeria has Africa’s largest population by far. Outside Africa, using Brazil as an example, only one of the top ten malaria endemic areas, Goias, was in the country’s top ten COVID-19 mortality count, at 8th place as of September 2022.33,44 Meanwhile, Brazil was the world’s second most affected country by COVID-19 mortality at the time.1

In addition to *Plasmodium* spp., other pro-inflammatory pathogens including helminths and human coronaviruses as may be common and/or endemic in many parts of Africa could potentially have similar effects.23,45–47 It is unclear, however, whether their effects may be as protective as the malaria effect we allude to. Human coronaviruses (HCoV), for example, have been suggested to play a role in the apparent protection from SARS-CoV-2 due to the observed cross-reactivity between HCoV-exposed sera and SARS-CoV-2 antigen.21,48 However, a contrasting observation suggests that pre-exposure to certain HCoV variants correlates positively with severity of COVID-19.49

**Low-grade inflammation**

Low-grade inflammation (LGI) is a state of persistent, low level systemic inflammation marked by approximately 2–4-fold increases in circulating immune pro-inflammatory markers.50–53 LGI may be due to chronic exposure to stimulatory environmental and lifestyle factors including stress, asymptomatic infections, bad oral hygiene practices, bad diet, obesity, traumatic injury, sedentary behaviour, and smoke inhalation.50,54,55 The third world living conditions across much of Africa have long fuelled a suspicion that LGI might be a relatively widespread phenomenon. Recently, this
At the start of the pandemic, it was predicted that individuals with underlying chronic disease conditions that have systemic inflammation as a common feature would be prone to more severe forms of COVID-19. The expectation was that due to the pre-existing immune inflammatory dysfunction, the inflammatory response of such individuals would quickly spiral into hyperinflammation in response to SARS-CoV-2 infection. The situation would be similar for people with low grade inflammation or inflamm-aging but who did not yet have full-blown chronic diseases. This, however, appears not to have been the case. Looking at obesity for example, which is a model for LGI, a recent study on patients in America reported that in the first few days after diagnosis, levels of selected inflammation markers were lower in obese COVID-19 patients than in non-obese patients. Previous studies on influenza had reported that obese individuals (with LGI) mounted a slow pro-inflammatory response to the respiratory virus, with impaired pathogen-induced and lung-specific responses. This impaired adaptive pro-inflammatory response was suggested to contribute to the worse COVID-19 clinical outcomes in obese patients. In contrast, we suggest that the delayed response is rather protective, much like in the case of malaria exposure previously described. The worse COVID-19 outcomes in obese patients are more likely found in those with underlying chronic inflammatory diseases and are probably due to a combination of factors including extensive dysfunction and dysregulation of the inflammatory response. We suggest that, after an inflammatory response is mounted in patients with inflammation-related comorbidity, appropriate metabolic regulation of the response is easily overwhelmed. In individuals with only LGI, however, the inflammatory dysfunction is present but is not so extensive as to have caused organ damage and subsequent chronic disease. The already higher circulating levels of inflammatory mediators in LGI individuals feed an ‘impaired’ adaptive immune inflammatory response. Therefore, there is a slow ramp-up of the pro-inflammatory response coupled with appreciable inflammatory response regulation (unlike in obese individuals with full-blown comorbidities, for example), a combination which tends to be protective against COVID-19 progression. This suggestion is backed by recent findings from across Europe, America and Asia to indicate that being overweight or obese increased the risk of COVID-19-related hospitalization but not mortality. Importantly, the risk of mortality for obese patients was not different from non-obese individuals. However, extreme obesity, which was more likely to be associated with comorbidities, increased the risk of mortality.

Further backing is from the observation that with the start of vaccination against COVID-19, literature from outside Africa suggested that older adults were less likely to report adverse effects after vaccination. Our interpretation of this is that the phenomenon of inflamm-aging, which has characteristics similar to low grade inflammation, appears to protect against the side effects attributable to the transient acute inflammatory response to some COVID-19 vaccines. This implies that the combination of higher systemic levels of inflammatory mediators, a blunt pro-inflammatory adaptive immune response, and an apparently impaired innate immune response are useful against COVID-19. We propose, however, that in our malaria-endemic populations, the innate response is not impaired. Rather, as described in the previous section, the history of frequent exposure to pro-inflammatory pathogens leaves the innate response at a higher level relative to individuals from other populations. This may explain why even older Africans appear to have better protection from the virus than older adults from elsewhere. The imprint of immune history on the specific modifications to an individual’s immune response would be consistent with the concept of immunobiography, which suggests close links between human health, longevity and individual immune system modifications.

**Outlook**

The focus on COVID-19 characterization and management had been on the clinical presentation of acutely ill patients. Only approximately 14% of COVID-19 cases are severe enough to require hospital admission. References to the 86% majority who experienced only mild/moderate or asymptomatic COVID-19 usually had to do with the tracking of the infection rate and transmission dynamics. Given the indications that an individual’s systemic inflammation state is altered post SARS CoV-2 infection, there had been the suspicion that even people with asymptomatic infection or mild COVID-19 symptoms would experience some sort of post-acute syndrome. Reports from across the world have indicated such a situation, showing that up to 50% of non-hospitalized patients who experience mild or moderate COVID-19 continue to have symptoms up to six months and beyond after recovery. This has since been termed post-acute sequelae of COVID-19 (PASC). Health issues associated with PASC include fatigue, exercise intolerance, cognitive impairment, anxiety/depression, organ damage, impaired mobility, and reduced quality of life, all of which are also associated with LGI and inflamm-aging.
The prevailing social and environmental conditions across Africa likely mean that the spread of SARS-CoV-2 has been rather extensive. This is supported, for example, by the observation of up to 41% average seroprevalence of SARS-CoV-2 antibodies in randomly sampled individuals across Ghana, compared to official figures of approximately 0.54% for cumulative total infection rate as of September 2022. Similar situations have been reported in other African countries. In a report from Ghana, where the 60+ age group showed the highest seropositivity rates, the antibody test kit that was used had shown up to 66% sensitivity and at least 94% specificity, the report suggested that the observation of low sensitivity of antibody test kits may be due to generally low production of antibodies by infected persons rather than a failure of the kits used. The low sensitivity was rather curious, particularly when earlier studies had reported significant cross-reactivity between previous human coronaviruses antibodies and SARS-CoV-2 antigens. Nevertheless, the overall indication was a gross underestimation of seropositivity, suggesting that far more people than officially reported were likely to have had SARS-CoV-2 infections which were unaccounted for. Such a phenomenon would lend support to our suggestion that some populations in Africa may exhibit a blunted, pro-inflammatory adaptive response to SARS-CoV-2 infection.

The occurrence of post-acute sequelae of COVID-19 lends credence to the suggestion that SARS-CoV-2 infection alters the inflammatory state. Infection with the virus has been shown to be widespread and relatively common across parts of Africa. Currently, ongoing works across 13 of Ghana’s 16 administrative regions report over 80% SARS-CoV-2 antibody prevalence, with no contribution from vaccination, between June 2021–June 2022 (unpublished work from Rockefeller Foundation Grant Number 2021 HTH 006; and FCDO Activity Number GB-1-203640-110). In relation to COVID-19 vaccination, our expectation has been that a potential long-term effect would be similar to the immune imprint and the alteration to the immune response due to SARS-CoV-2 infection, as can be deduced from recent reports. As has been found recently, SARS-CoV-2 reinfections appear to have a cumulative negative effect. It is essential, therefore, that studies are conducted to appreciate the potential impact of the apparently widespread but asymptomatic SARS-CoV-2 infections. It is important to understand what changes in the inflammatory state have occurred post SARS-CoV-2 infection in our African populations, to help to characterize and preempt the effects on public health.

Data availability
No data are associated with this article.

Authors’ contributions
Daniel Oduro-Mensah: Conceptualization, Writing – original draft, Writing – review and editing. Ebenezer Oduro-Mensah: Writing – original draft, Writing – review and editing. Peter Quashie: Writing – review and editing. Gordon Akanzuwine Awandare: Writing – review and editing. Laud Kenneth Okine: Writing – original draft, Writing – review and editing.

Acknowledgements
The authors acknowledge the contributions of Nana Tawiah Ghunney and Stephanie Nannelle Hammond to the preparation of this manuscript.

References
3. Europe is struggling to contain the third wave of the epidemic. CNN. Accessed March 16, 2021. Reference Source
70. Contributors: Links Between COVID-19 Comorbidities, Mortality
Reference Source

Publisher Full Text

Reference Source

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text
Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

Publisher Full Text

113. Al-Aly Z: Outcomes of SARS-CoV-2 Reinfection. Published online June 17, 2022.  
Publisher Full Text
Open Peer Review

Current Peer Review Status:  

Version 1

Reviewer Report 30 August 2022

https://doi.org/10.5256/f1000research.78107.r146899

© 2022 Chakrabarti S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sankha S. Chakrabarti

Department of Geriatric Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India

This is an interesting hypothesis article. There are some minor grammatical errors. Please correct those.

- Example: "From December 2020 when emerging SARS-CoV-2 variants fueled second and third waves of COVID-19 across the globe from December 2020," - Here, "From December 2020" is repeated twice. Go through the entire text and check carefully.

My other suggestions are:

1. Mention low vaccine coverage as a possible reason. Though it may seem unusual, the data for most countries with high vaccination rates such as Israel or South Korea show rising cases post-vaccination and even after boosters.

2. The preferred abbreviation for alanine aminotransferase is ALT. Please correct.

3. The part about obesity and low reactogenicity of vaccines in the elderly as support for the authors' hypothesis is unclear and does not seem convincing. More proof and clarity is needed, or better to delete.

4. "Interestingly, the 60+ age group showed the highest seropositivity rate. Keeping in mind that the antibody test kit used had shown up to 66% sensitivity and at least 94% specificity, the report suggested that the observation of low sensitivity of antibody test kits may be due to generally low production of antibodies by infected persons rather than a failure of the kits used. The low sensitivity is interesting, particularly when some studies report significant cross-reactivity between other human coronaviruses antibodies and SARS-CoV-2 antigens. The likely underestimation of seropositivity suggests that far more people than officially reported are likely to have had SARS-CoV-2 infections which are unaccounted for." - This part needs to be re-written for clarity. Also, reference 106 at the end of the first sentence is not linked as a reference. Please correct.
5. The final part (last two paragraphs) are not written in synchrony. The authors have mixed up some important points they wish to make. Please re-write for clarity.

Overall, the authors start off well but they have not separated the valid points they wish to make clearly in the rest of the article which makes it difficult to understand.

**Is the background of the case's history and progression described in sufficient detail?**
Yes

**Is the work clearly and accurately presented and does it cite the current literature?**
Partly

**If applicable, is the statistical analysis and its interpretation appropriate?**
Not applicable

**Are all the source data underlying the results available to ensure full reproducibility?**
Partly

**Are the conclusions drawn adequately supported by the results?**
Partly

**Is the case presented with sufficient detail to be useful for teaching or other practitioners?**
Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** COVID vaccines, Geriatric pharmacovigilance, Geriatric neuropsychiatry

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 13 Sep 2022

**Daniel Oduro-Mensah**, University of Ghana, Accra, Ghana

The authors sincerely appreciate the time and effort the reviewer has spent to make the report better.

We take note of the reviewer’s comments and respond as follows:

1. We appreciate the reviewer’s suggestion in comment 1 to add to our explanations in the manuscript. However, we believe that it would be a full discussion for another platform. Our thinking about vaccination, as relates to what is presented in this manuscript, has been touched on briefly in the conclusion section.

2. The abbreviation has been corrected to ALT. Thank you very much for the notice in reviewer's comment 2, that was an oversight.
3. The authors remain committed to the suggestions and inferences the manuscript makes in the section referred to in reviewer's comment 3. The section has been rewritten and strengthened with further evidence as the reviewer suggested.

4. The section referred to in reviewer's comment 4 has been rewritten for clarity as suggested by the reviewer.

5. The last two paragraphs have been rewritten as suggested in reviewer's comment 5. A portion has been broken off to make a conclusion section.

**Competing Interests**: No competing interests are declared.